Evidence map›Paper›PMID 39161671›Full record

ArticleClinical case reports2024

Concomitant manifestations of systemic lupus erythematosus flare-up and nodal marginal zone B-cell lymphoma in a 41-year-old male patient: A challenging case report.

Mohammadkian Zarafshani, Ehsan Rahmanian, Reza Manouchehri Ardekani, Seyed Amir Hassan Matini, Maryam Loghman, Seyedeh Tahereh Faezi

Abstract readCase Reports
In one paragraph

Article in Clinical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohammadkian ZarafshaniRheumatology Research Center, Shariati Hospital Tehran University of Medical Sciences Tehran Iran.ORCID https://orcid.org/0000-0002-3772-0349
Ehsan RahmanianDepartment of Rheumatology, Shahid Sadoghi Hospital Yazd University of Medical Sciences Yazd Iran.ORCID https://orcid.org/0000-0002-1491-3658
Reza Manouchehri ArdekaniAutoimmune Disease Research Center, Beheshti Hospital, Department of Hematology Kashan University of Medical Sciences Kashan Iran.
Seyed Amir Hassan MatiniDepartment of Clinical Pathology Beheshti Hospital, Kashan University of Medical Sciences Kashan Iran.ORCID https://orcid.org/0000-0002-9106-0249
Maryam LoghmanAutoimmune Disease Research Center, Beheshti Hospital, Department of Rheumatology Kashan University of Medical Sciences Kashan Iran.ORCID https://orcid.org/0000-0002-1729-3028
Seyedeh Tahereh FaeziRheumatology Research Center, Shariati Hospital Tehran University of Medical Sciences Tehran Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Key Clinical Message: Malignancy may be a possible cause of systemic lupus erythematosus (SLE) flare-ups, and it is necessary to consider it in the context of treatment resistance. In this case, we present a challenging instance of concomitant nodal marginal zone B-cell lymphoma (NMZL) and SLE flare-up in a 41-year-old male patient. Abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can cause various symptoms and affect multiple organs in the body. It is also associated with the development of malignancies, especially lymphomas. This case report discusses a patient who experienced a flare-up of SLE along with hypercalcemia, which led to the diagnosis of nodal marginal zone B-cell lymphoma (NMZL). This is the first case of its kind to be reported. A 41-year-old man with a 10-year history of SLE and antiphospholipid syndrome (APS) was referred to our center due to several symptoms, including fatigue, oral lesions, dyspnea, bilateral wrist pain and inflammation, mild pericardial effusion, organ enlargement, pancytopenia, high erythrocyte sedimentation (ESR) level, high anti-double stranded DNA (anti-dsDNA) level, low complement level, resistant hypercalcemia, and high brain natriuretic peptide (pro-BNP) level. After further testing, it was discovered that the patient had NMZL, which was the ultimate diagnosis. He underwent six cycles of the R-CHOP chemotherapy regimen, and his clinical and laboratory conditions improved during follow-ups. The initial case of SLE flare-up, with concomitant NMZL is being reported as the final diagnosis. In simpler terms, it is possible for lymphoma to manifest as a potential cause of SLE flare-ups, and clinicians should be mindful that they need to consider malignant conditions when faced with treatment resistance.

Indexed as

autoimmune reactionhypercalcemiamalignancynodal marginal zone B‐cell lymphomasystemic lupus erythematous

Identifiers

PMID39161671
PMCPMC11331144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.